Results 211 to 220 of about 23,286,365 (332)
Outcomes of team based learning in teaching medical ethics: a systematic review. [PDF]
Alizadeh M +3 more
europepmc +1 more source
Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease
ABSTRACT Objective To characterise the progression of motor symptoms and identify eligibility for device‐aided therapies in Parkinson's disease, using both the 5‐2‐1 criteria and a refined clinical definition, while examining differences across genetic subgroups.
David Ledingham +7 more
wiley +1 more source
Correction: Does papillary muscle free strain has predictive value in risk stratification of patients with hypertrophic cardiomyopathy? [PDF]
PLOS One Editors.
europepmc +1 more source
ABSTRACT Objective Cognitive impairment, fatigue, and depression are common in multiple sclerosis (MS), potentially due to disruption of regional functional connectivity caused by white matter (WM) lesions. We explored whether WM lesions functionally connected to specific brain regions contribute to these MS‐related manifestations.
Alessandro Franceschini +7 more
wiley +1 more source
Could lessons from medical research ethics inform better conversations and governance for climate engineering research. [PDF]
Fitzgerald SD +3 more
europepmc +1 more source
Conducting Ethics Research in Prison: Why, Who, and What?
D. Shaw, T. Wangmo, B. Elger
semanticscholar +1 more source
ABSTRACT Background Poststroke fatigue (PSF) and frailty share substantial overlap in their manifestations, yet previous research has yielded conflicting results due to the use of heterogeneous frailty assessment tools. Objective To evaluate the independent impact of frailty on PSF using a unified measurement system (Tilburg Frailty Indicator, TFI ...
Chuan‐Bang Chen +6 more
wiley +1 more source
Correction: PM2.5 risk perception and associated with sociodemographic factors in urban Thailand. [PDF]
Luangwilai T +4 more
europepmc +1 more source
ABSTRACT Objective Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is a progressive neuromuscular disorder with no approved treatments. Identifying reliable biomarkers is critical to monitor disease severity, activity, and progression. Interleukin‐6 (IL‐6) has been proposed as a candidate biomarker, but longitudinal validation is limited ...
Jonathan Pini +13 more
wiley +1 more source

